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Summary 
Background 
Non-alcoholic fatty liver disease is the fastest growing cause of liver disease in the Western world, 
yet there is no approved pharmacotherapy. While lifestyle modifications remain the mainstay of 
treatment, only a proportion of individuals are able to make or sustain them, and so more treatment 
options are required.  
Aim 
To review the potential benefit of drugs used in clinical practice, those entering phase II trials, and 
compounds being investigated in preclinical studies. 
Methods  
A literature search was performed using PubMed to identify relevant studies; linked references were 
also reviewed. 
Results  
Vitamin E and pioglitazone have shown efficacy in NASH, but long-term safety concerns, specifically 
bladder cancer and osteoporosis with pioglitazone, have limited their use. GLP-1 analogues and 
SGLT-2 inhibitors are currently approved for use in diabetes, have sho n early efficacy in NASH and 
also have beneficial cardiovascular effects.  PPARα/δ and FXR agonists have potent effects on 
lipogenesis, inflammation and fibrosis respectively, with their efficacy and safety being currently 
tested in phase 3. As inflammation and apoptosis are key features of NASH agents modulating these 
pathways are of interest; CCR2/5 antagonists downregulate inflammatory pathways and reduce 
fibrosis with caspase and apoptosis signal-regulating kinase 1 (ASK1) inhibitors reducing apoptosis 
and fibrosis.  
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Conclusions 
Rising demand and an improved understanding of NASH pathophysiology has led to a surge in 
development of new therapies. Tailoring pharmacotherapy to the dominant pathogenic pathway in a 
given patient along with use of combination therapy is likely to represent the future direction in 
treatment of patients with NASH.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
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Non-alcoholic fatty liver disease, defined as accumulation of excess fat in the liver, is the commonest 
cause of liver disease in Western countries. In the United States it is estimated to affect between 3 
to 40% of individuals (1, 2) and is predicted to become the leading cause of liver transplantation over 
the next 10 years (3). Non-alcoholic steatohepatitis is mediated by inflammatory cytokines, 
mitochondrial dysfunction secondary to nutrient excess and oxidative stress (4, 5), resulting in 
hepatocyte inflammation, ballooning, apoptosis, and activation of hepatic stellate cells (HSC). These 
differentiate into a proliferative, contractile and matrix-secreting phenotype, depositing collagen I, 
and promoting liver fibrosis (6), which affects approximately one third of patients with NAFLD (7).  
Weight loss, as part of lifestyle change, is the only recommended intervention, with a loss of >7% 
total body weight associated with clearance of histological NASH and a >10% loss associated with an 
improvement in fibrosis.  However, even within trial settings where motivation is usually high, less 
than 20% achieve >7% weight loss, and so alternative treatments need to be found (8).   
There remains uncertainty as to which patients with NASH need to be treated; cardiovascular and 
liver-related mortality and morbidity is directly related to fibrosis stage, and so patients with 
evidence of progressive fibrosis should be identified and prioritised (9, 10). Indeed, cardiovascular 
disease is the leading cause of death in NAFLD (10) and so emerging pharmacotherapy should ideally 
aim to reduce both liver-related and cardiovascular mortality.    
Medications currently taken by patients with NASH target concomitant features of the metabolic 
syndrome such as hypertension, dyslipidaemia and diabetes (11). Agents such as Vitamin E and 
pioglitazone are recommended (11, 12), with caveats, for selected patients with NASH although 
there remain concerns about their side-effect profile. This review will consider medications currently 
used routinely in NAFLD clinics; those currently in phase II trials, and finally those compounds with 
promising preclinical data. Table 1 summarises the drugs that have evidence of efficacy in NAFLD, 
their proven histological and non-histological benefits.  
 
Page 4 of 34Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
5 
 
Medications currently used in patients with NASH to treat co-morbidities 
1. Dyslipidaemia and hypertension 
Dyslipidaemia and hypertension should be managed according to evidence-based guidelines and 
should reduce cardiovascular morbidity and mortality in patients with NASH. Statins are not only 
safe in NASH (13) but are also associated with a reduced mortality (14). Fibrates are synthetic 
agonists of PPARα, but have not shown benefit in NAFLD outside the management of 
hypertriglyceridaemia (15). 
There are no particularly favoured agents for control of hypertension, although some studies have 
suggested that angiotensinogen receptor blockers may have additional anti-fibrotic effects, albeit 
with small participant numbers (15, 16).   
 
2. Weight management  
Orlistat, a gut lipase inhibitor, reduces absorption of dietary fats, and is approved in obesity as an aid 
to weight loss in conjunction with a hypocaloric diet (17). Several studies have investigated orlistat in 
NAFLD, with conflicting results; one study comparing 9 months of hypocaloric diet plus vitamin E 
with diet plus thrice daily 120 mg orlistat showed improved insulin sensitivity (P < 0.001), 
adiponectin (P = 0.03), steatosis (P = 0.005), ballooning (P = 0.04), inflammation (P = 0.045), and NAS 
histology score (P = 0.009) in those who lost ≤9% body weight, but showed no correlation with the 
use of orlistat (18). Conversely, a smaller study comparing the same dose of orlistat with placebo for 
6 months in subjects with biopsy confirmed NAFLD showed improved ALT and steatosis by USS in the 
orlistat group despite similar changes in weight in the two groups (19); similar results were seen in a 
more recent study following 4 months of treatment (20). Thus, Orlistat remains a part of weight-loss 
strategies with insufficient data for its use in NAFLD alone. 
3. Management of diabetes 
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a) Metformin 
Metformin is the first line agent for type 2 diabetes mellitus (T2DM), and reduces the risk of all 
diabetes-related end-points including microvascular disease, myocardial infarction, large vessel 
disease, and cardiovascular mortality, in addition to aiding weight loss (21).  Although studies have 
not demonstrated any improvement in liver enzymes or liver histology (22), there is epidemiological 
evidence to suggest it is associated with a reduced incidence of both liver and non-liver malignancies 
including hepatocellular carcinoma (HCC) in those with NASH cirrhosis by as much as 7% (23, 24).   
 
b) GLP-1 and DDPIV inhibitors 
Glucagon-like peptide-1 (GLP-1) is a gut-derived hormone analogue that induces insulin secretion, 
reduces glucagon secretion, suppresses appetite and delays gastric emptying (25). This class of drugs 
is licensed for the treatment of diabetes and obesity, improvement of both of which is desirable in 
patients with NASH. GLP-1 analogues have been shown to improve liver histology in murine models 
of non-alcoholic steatohepatitis (26, 27), reduce liver enzymes in patients with T2DM (28, 29) and in 
clamp studies lead to a reduction in de novo lipogenesis and an increase in fatty acid oxidation in the 
liver (29-31)  
Liraglutide 
Liraglutide is a long-acting GLP-1 analogue which has been shown to induce improvements in 
peripheral, hepatic and adipose insulin resistance, and reductions in de novo lipogenesis in subjects 
with NASH (31). In a phase II 48-week randomised controlled trial liraglutide met its primary end-
point and induced resolution of NASH in both diabetic and non-diabetic patients as well as improving 
steatosis and ballooning. It was not possible to establish whether these histological effects were 
solely determined by beneficial effects on weight, although there was a suggestion that the benefit 
remained after controlling for weight loss (32). Both liraglutide and the more biologically active 
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semaglutide reduced event rates in large cardiovascular outcome studies (33, 34). Semaglutide 
reduced rates of nonfatal myocardial infarction (2.9% vs 3.9%), and nonfatal stroke (1.6% vs 2.7%) 
compared with placebo in 1648 patients with type 2 diabetes who took 0.5 or 1.0 mg semaglutide 
weekly for 104 weeks, although death from cardiovascular cause was similar in the two groups (2.7% 
vs 2.8%). Notably, there was an increased risk of retinopathy (3.8% vs 1.8%) in the treated groups, 
which requires further monitoring and, like liraglutide, gastrointestinal side effects were common, 
which was the primary reason for discontinuation of treatment (33). Semaglutide is currently being 
examined in a phase II trial of patients with NASH and fibrosis (NCT02970942).       
 
Dipeptidyl peptidase-4 (DDP-4) rapidly degrades endogenous GLP-1, and a pilot study of sitagliptin, a 
selective DDP-4 inhibitor, demonstrated an improvement in liver histology in diabetic patients after 
1 year of treatment but included only 15 participants and no control arm (35).  Reduction in liver fat 
content using magnetic resonance spectroscopy (MRS) has also been demonstrated following 24 
weeks of sitagliptin or vildagliptin therapy (36). However, three subsequent studies have failed to 
show an effect of sitagliptin treatment on liver fat content (36), liver enzymes (37) or liver stiffness 
(38), and currently its use is reserved for the management of diabetes.  
 
c) Sodium glucose co-transporter 2 (SGLT2) inhibitors 
The sodium glucose co-transporter 2 is primarily expressed in the renal proximal tubules, and 
reabsorbs 90% of glucose filtered at the renal glomeruli; inhibition therefore facilitates urinary 
glucose excretion, and SGLT2 inhibitors are used in diabetes to improve plasma glucose levels and 
promote weight loss (39). A meta-analysis of placebo controlled randomised control trials for SGLT2 
inhibitors showed improved all-cause (OR 0.72; 95% CI 0.59–0.86; P < 0.001), and cardiovascular 
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mortality (OR 0.67; 95% CI 0.51–0.87; P = 0.003), for empagliflozin but not all agents, suggesting it 
may not be a class effect (40, 41). 
Several SGLT2 inhibitors have shown benefit in murine models of NAFLD, improving steatosis, 
inflammation, and fibrosis (42-45), and studies in humans with T2DM have demonstrated improved 
ALT and weight loss in patients with type 2 diabetes with ipragliflozin and canagliflozin (46, 47), as 
well as reducing fatty liver index score (from 70.1 ± 19.4 to 60.3 ± 25.5, P = 0.0009) with ipragliflozin 
(48).  There are no reported human studies assessing changes in liver histology in NAFLD with SGLT2 
inhibitors, although one study did demonstrate weight-independent improvements in serum ALT 
with ipragliflozin (44).  
Dapagliflozin, canagliflozin and empagliflozin are currently approved for use in patients with T2DM, 
although some safety concerns have emerged from phase III trials and post marketing surveillance 
regarding urinary tract infections (UTI).  Th  presence of urinary glucose is thought to increase the 
risk of mild genital mycotic infections and urinary tract infections (49, 50). Pooled data from 
randomized controlled trials showed that UTIs occurred in 3.8% of patients receiving placebo versus 
5.9% and 4.4% of those receiving canagliflozin 100 mg and 300 mg once daily, respectively (50). 
Similar rates of UTIs were reported for dapagliflozin, (3.7% for placebo vs 5.7% and 4.3% for 
dapagliflozin 5 mg and 10 mg once daily, respectively) (51), and empagliflozin 10 mg once daily (9.3% 
vs 7.6% on placebo), although UTI rates for 25mg empagliflozin were the same as for placebo. (52). 
Post-marketing reports of cases of potentially fatal urosepsis, pyelonephritis and DKA in patients 
receiving SGLT2 inhibitors led to a warning from the FDA 2015 about the possibility of severe urinary 
tract infection and pyelonephritis with these agents (53). 
In post-marketing studies, dual-energy X-ray absorptiometry revealed small but statistically 
significant reductions in bone mineral density (BMD) at the hip (placebo subtracted changes of –
0.9% and –1.2% for the 100- and 300-mg dose groups, respectively) but no other sites (54) . The 
same risks do not appear to be associated with dapagliflozin or empagliflozin use (49, 55). Pooled 
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data for canagliflozin from nine clinical trials with a mean treatment time of 85 weeks reported 
incidence rates for bone fractures of 1.4 and 1.5 per 100 patient-years for those on 100mg and 300 
mg of canagliflozin, respectively, vs 1.1 per 100 patient-years for those on placebo (31).  
 
d) TZD 
Peroxisome proliferator-activator receptors (PPARs) are nuclear receptors that play key roles in the 
regulation of lipid metabolism and insulin sensitivity, and recently have been implicated in pathways 
of inflammation and atherosclerosis (56).  Drugs targeting PPAR receptors include pioglitazone, 
sometimes used in patients with NASH, as well as elafibranor, fibrates and saroglitazar, which were 
primarily developed to improve dylipidaemia, but may have additional benefit in NAFLD.  
 
Whilst this class of drugs can be used in the treatment of diabetes, there has been use specifically to 
treat NASH. Pioglitazone is a PPARγ agonist that has been shown to improve hepatic steatosis, 
inflammation and fibrosis in a meta-analysis including both diabetic and non-diabetic patients with 
NASH (57).  Other meta-analyses demonstrated cardiovascular benefit, with a reduction in death, 
myocardial infarction and stroke from 5.7% to 4.4% in patients with T2DM, the optimum benefit 
being seen after one year of therapy (58).  Notably, in the PIVENS trial of 247 non-diabetic adults 
with NASH randomised to receive pioglitazone, vitamin E or placebo, for 96 weeks, pioglitazone did 
not meet its primary end-point although it demonstrated a reduction in hepatic steatosis (p<0.001), 
lobular inflammation (p=0.004) and serum alanine and aspartate aminotransferase levels (p<0.001). 
However, subjects receiving pioglitazone gained more weight than those who received vitamin E or 
placebo (59), a side effect seen in several other studies. There has been other concerns regarding 
the long-term safety of pioglitazone; two meta-analyses found an increased risk of congestive 
cardiac failure despite reductions in other cardiovascular mortality, and in the study by Lincoff et al, 
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heart failure was reported in 200 (2.3%) of the pioglitazone-treated patients compared with 139 
(1.8%) of the control patients (HR, 1.41; 95% CI, 1.14-1.76; P = 0.002)(58, 60). A study based on 
adverse event reporting to the United States Food and Drug Administration (FDA) demonstrated an 
increased risk of bladder cancer with a relative odds ratio of 4.30 (95% CI 2.82-6.52) for pioglitazone 
compared with other antidiabetic medications (61). A more recent UK study with 689,616 person-
year follow-up reports the risk of bladder cancer for pioglitazone vs other medications as 121.0 v 
88.9 per 100 000 person years (HR 1.63, CI 1.22 to 2.19) (62), and the FDA have reiterated their 
warning about the risks.  In addition, PPAR-γ activation increases bone resorption while decreasing 
bone formation, increasing the risk of osteoporosis, which is already a concern in those with 
diabetes (63). EASL and AASLD guidelines currently recommend pioglitazone for NASH, albeit with 
careful consideration of the potential long-term risks (11, 12).    
 
Saroglitazar is a dual PPARα/γ agonist in clinical use, approved for the treatment of dylipidaemia in 
diabetic patients in India. In mouse models of NASH it decreased liver fat content and induced 
histological improvement (64), and retrospective analysis of a phase III trial conducted in diabetic 
patients with triglyceridaemia demonstrated a reduction in ALT without significant weight gain after 
24 weeks of 2 or 4 mg saroglitazar (65). A smaller, open label phas  II study in 32 patients with 
NAFLD and diabetes showed improvements in ALT, HBA1c, serum triglycerides and steatosis on USS 
following 24 weeks of treatment (66), and a further phase II trial comparing 3 doses of saroglitazar 
with placebo in NAFLD is planned (NCT03061721). 
 
Elafibranor (GFT505) is an unlicensed dual agonist of the PPARα and δ receptors, and has been 
shown to improve lipid and glucose metabolism in type 2 diabetes mellitus (T2DM), and steatosis, 
inflammation and fibrosis in mouse models of NAFLD (67). A small study in 22 obese men has shown 
that GFT505 improved peripheral and hepatic insulin sensitivity, and significantly reduced plasma 
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free fatty acid concentrations, fasting plasma triglycerides and LDL cholesterol (68). Post hoc analysis 
of the GOLDEN-505, phase IIb randomised placebo controlled study, showed patients clearing NASH 
(as defined by disappearance of ballooning together with either disappearance of lobular 
inflammation or the persistence of mild lobular inflammation (score of 0 or 1) without worsening of 
fibrosis) with 120 mg oral elafibranor in those with NAS≥4 (19% vs 9%; p=0.013).  Treatment was not 
effective in those with NAS ≤4 (19% vs 12%; p=0.045) (69, 70). A phase III trial is now evaluating the 
ability of elafibranor (dose 120mg od) to achieve resolution of NASH with no worsening of fibrosis 
after 72 weeks of treatment. (NCT02704403).  
 
MSDC-0602 is a next-generation TZD with a diminished peroxisome proliferator–activated receptor γ 
(PPARγ) activity, stimulation of which is believed to cause the weight gain, oedema, and increased 
risk of fractures associated with usual TZD use. It is hoped that a PPARγ sparing TZD, may have some 
of the same benefits on insulin sensitivity and hepatic steatosis via the mitochondrial target of 
thiazolidinediones (mTOT), while sparing some of the associated side effects (71). In diabetes, a 
proof of concept study showed similar reductions in fasting glucose and HBA1c compared with 
pioglitazone, with reduced fluid retention and a lesser increase in adiponectin (suggestive of weight 
gain) following 12 weeks of treatment (72).  Animal models of NASH have demonstrated reduced 
transaminases, histological NASH, and stellate cell activation following MSDC-0602 treatment (73), 
and a phase IIb study evaluating three doses of MSDC-0602K with a primary outcome of NAS 
improvement with no worsening of fibrosis after 12 months of treatment, is currently recruiting 
(NCT02784444). 
 
Medications currently used to treat patients with NASH  
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Vitamin E is the most widely investigated antioxidant, with the potential to reduce oxidative stress in 
NASH. It has been shown to improve steatosis and inflammation in several RCTs in both diabetic and 
non-diabetic children and adults, although trials have been heterogeneous, comparing different 
doses of vitamin E against various agents as well as placebo (74, 75). In two studies weight loss may 
have accounted for some of the histological changes seen, making it difficult to draw robust 
conclusions. In the PIVENS trial, the arm taking 800mg/day of vitamin E met the primary end-point 
which was reduction in NAFLD Activity Score (43% vs. 19% in placebo; p =0 .001) but notably did not 
result in resolution of NASH. It reduced liver steatosis (p = 0.005) and ALT levels (P <0 .001), but had 
no effect on liver fibrosis (p = 0.240) (59); similar results were seen in children and adolescents in the 
TONIC RCT (75). However, concerns regarding the risk of prostate cancer and haemorrhagic stroke 
(50, 51) have limited its use. The SELECT study compared selenium vs vitamin E vs placebo for a 
primary outcome of Gleason grade ≥7 prostate cancer, and showed an increased relative risk of 17% 
with vitamin E (76). However, it is possible that single nucleotide polymorphisms (SNPs) affecting 
vitamin E metabolism may be responsible for the increased risk, as absolute risk of prostate cancer 
was lower at 1.6 per 1000 person-years (76). Furthermore, a meta-analysis investigating the effect of 
vitamin E on the incidence of stroke reported an increase in the relative risk of haemorrhagic stroke 
by 22%, while the risk of ischaemic stroke was reduced by 10% (77).  Despite the potential benefits 
in NASH, the risks and benefits of therapy must be carefully discussed with patients in clinical 
practice. 
 
Drugs in Phase II/III development  
The therapeutic landscape for NASH is evolving rapidly with many compounds currently being 
assessed in phase II/III clinical trials. As detailed in this section these agents are targeting multiple 
aspects of the pathogenesis of NASH. Table 2 indicates the histological benefits demonstrated in 
patients with NAFLD and table 3 shows non-liver related benefits related to drugs used in NAFLD.   
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a)  Farnesoid X receptor (FXR) bile acid axis  
The nuclear hormone farnesoid X receptor (FXR) is primarily expressed in the liver, intestines, and 
kidneys, and has a key role in bile acid synthesis, and also influences carbohydrate and lipid 
metabolism, and insulin sensitivity (78).  Both conjugated and unconjugated bile acids are the 
natural ligand of FXRs and can active the receptor at any point in the enterohepatic circulation (78, 
79). In animal models, FXR activation has been demonstrated to reduce hepatic gluconeogenesis, 
lipogenesis and steatosis (79-81), and both synthetic bile acid variants (namely obeticholic acid, OCA) 
and non-bile acid FXR agonists have been developed and are currently being tested in clinical trials. 
 
Obeticholic acid (OCA) is a synthetic variant of the natural bile acid chenodeoxycholic acid, a potent 
activator of the farnesoid X nuclear receptor, which negatively regulate bile acid synthesis and 
down-regulates lipogenesis (81). The FLINT study, a multicentre, phase IIb clinical trial conducted in 
subjects with subjects with NASH (NAS>4), compared placebo (n=142) with 25mg obeticholic acid 
(n=141) for 72 weeks. OCA met the pre-defined stopping rule for efficacy, namely reduction in the 
NAFLD activity score (NAS) by 2 points with no worsening in fibrosis, although it did not impact on 
resolution of NASH (22% in OCA arm vs 13% in placebo arm; p=0.08). Notably, OCA improved fibrosis 
stage in 35% of patients vs 19% (p=0.004) in the placebo arm (82). Of note, although insulin 
resistance, as assessed by euglycaemic hyperinsulinaemic clamps, improved in an earlier study (83), 
the opposite finding was observed in the FLINT trial. Whilst this may relate to the imbalance in 
insulin values at baseline in the FLINT trial or the different methods used to assess insulin resistance 
in the two studies it will be an important consideration in the ongoing phase III trial (NCT02548351). 
Moreover, pruritus was reported in 23% of the treated group, which may be an important 
consideration for a condition with minimal symptoms (82). Given the increased risk of cardiovascular 
morbidity and mortality in patients with NASH, the increased levels of low-density lipoprotein (LDL) 
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and reduced levels of high-density lipoprotein (HDL) on OCA therapy are a concern and will require 
careful attention/management in future studies (82).    
Ursodeoxycholic acid (UDCA), a naturally occurring secondary bile acid, has not been shown to 
improve histological features of NASH (84, 85), and there is as yet no human histological data for  
the bile acid derivative tauroursodeoxycholic acid, or the UDCA derivative 24 norursodeoxycholic 
acid. 
Selective non-bile acid synthetic farnesoid X receptor agonists have been developed, which have the 
potential to provide the metabolic effects of FXR agonism without the side effects of pruritus and 
elevated LDL.  GS-9674 has been shown to significantly reduce serum transaminases, hepatic 
steatosis and fibrosis in murine models of NASH (86) and is being assessed at two dosages for 12 
weeks in patients with clinical, radiological or histological NAFLD (NCT02856555).  A further study 
compares GS-9674 with the Acetyl Co–A carboxylase inhibitor, GS-9676 (see lipid lowering drugs), 
and selonsertib, (apoptosis signal-regulating kinase 1 inhibitor), as well as selonsertib and GS-9674 in 
combination, for 12 weeks (NCT02781584).  
Two other FXR agonists, LMB763 and LJN452 have been developed and are in phase II trials.  A phase 
IIa study in patients with phenotypical or histological NASH for LMB763 is recruiting (NCT02913105), 
and LJN452 is being tested across a range of doses in patients with phenotypical or histological NASH 
and hepatic fat content >10% by MRI (NCT02855164). 
 
b) Bile acid sequestrants/transporter inhibitors 
Bile acid sequestrants bind bile acids in the gut and can be used to treat dyslipidaemia and 
hyperphosphatemia, although more recently these agents have been reported to lower blood 
glucose and increase insulin sensitivity through altered bile acid signalling pathways, possibly 
mediated by the presence of increased bile acids in the distal colon stimulating GLP-1 and peptide YY 
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(87). Whilst the bile acid sequestrant colesevelam was ineffective for the treatment of NASH, 
Sevelamer, a phosphate binding drug used to treat hyperphosphataemia in patients with chronic 
kidney disease, appeared more promising as it reduced steatosis and lobular inflammation in murine 
studies with a potential additional indirect impact on FXR signalling (79). 
 
In another approach, inhibitors of the ileal apical sodium-dependent bile acid transporter (ASBT) 
have been developed which target bile acid reabsorption in the terminal ileum, and have been 
demonstrated to improve glycaemic control in diabetic rats (87), and restore glucose tolerance, 
reduce hepatic triglyceride and total cholesterol concentrations, as well as improve NAS in HFD-fed 
mice (88). An oral inhibitor of ASBT, volixibat (SHP-626), was well tolerated in phase I studies (89) 
and a phase II trial in patients with NASH is currently enrolling (NCT02787304). 
 
c) Hormone signalling 
Fibroblast growth factor 21 is a hormone secreted predominantly from the liver, which acts primarily 
in the fasting state to coordinate carbohydrate and lipid metabolism, enhance insulin sensitivity, 
decrease triglyceride levels, and cause weight loss, thus ameliorating obesity-associated 
hyperglycaemia and hyperlipidaemia (90).  In animal models, an FGF-21 analogue (BMS-986036) 
improved insulin sensitivity, hepatic fat content, and de novo lipogenesis (91), and a subsequent 
phase II RCT is evaluating the effectiveness of 16 weeks of BMS-986036 treatment on hepatic fat 
content measured by magnetic resonance spectroscopy (MRS) in patients with NASH 
(NCT02413372). FGF-19 is another peptide hormone secreted in response to reabsorption of bile 
acids and FXR activation in the terminal ileum, reducing bile acid synthesis and gluconeogenesis 
independently of insulin (92).  NGM-282 is a recombinant variant of FGF-19 that has shown 
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reduction of hepatic fat, ALT and improved NAS scores in mouse models (93) and is currently in a 
phase II study (NCT02443116) in patients with biopsy-proven NASH. 
 
d) Anti-inflammatory and anti-apoptotic agents 
Cenicriviroc, a C-C chemokine receptor types 2 and 5 antagonist, has been shown to reduce CD14 
which is involved in inflammatory cell activation, and improve the aspartate aminotransferase-to-
platelet count ratio index (APRI) and fibrosis-4 scores in patients with HIV (94).  The C-C chemokine 
receptor types 2 and 5 (CCR2 and CCR5) and their respective ligands, C-C chemokine ligand types 2 
(CCL2/monocyte chemo attractant protein-1 [MCP-1]) and 5 (CCL5/RANTES) play a role in 
inflammatory cell recruitment to the liver and also the activation of hepatic stellate cells. In a phase 
II study in obese adults with NASH (NCT02330549) cenicriviroc showed a reduction in fibrosis scores, 
but did not meet its pre-defined primary end-point of a two-point reduction in NAFLD activity scores; 
primary analysis of a phase IIb study in NASH shows similar results (95, 96). 
Apoptosis signal-regulating kinase 1 (ASK1) is activated by extracellular TNFα, intracellular oxidative 
or endoplasmic reticulum stress and initiates the p38/JNK pathway, resulting in hepatocyte 
apoptosis and fibrosis (97). In animal models ASK1 inhibition reduced hepatic fibrosis, steatosis, and 
insulin resistance (98).  Two doses of an ASK1 inhibitor, selonsertib, in combination with 
simtuzumab, or alone, were studied in a phase II trial in patients with NASH and stage 2-3 fibrosis 
(NCT02466516).  Abstract data suggested that high dose selonsertib was effective at reducing 
fibrosis but did not improve the histological NAS score.  Side effects such as headache, nausea, and 
abdominal pain were more prominent, however, on higher dose combination therapy and are likely 
to remain a concern in longer term trials (99). 
The adhesion molecule vascular adhesion protein-1 (VAP-1), is a membrane-bound amine oxidase 
that promotes leukocyte recruitment to the liver, and its soluble form (sVAP-1) which accounts for 
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most circulating monoamine oxidase activity, has insulin-like effects and can initiate oxidative stress. 
An absence or blockade of functional VAP-1 in murine hepatic injury models has been shown to 
reduce inflammatory cell recruitment to the liver and attenuate fibrosis (100). Furthermore, serum 
sVAP-1 levels are elevated in patients with NAFLD compared with those in control individuals (100), 
and targeting VAP-1 is believed to have therapeutic potential for NAFLD and other chronic fibrotic 
liver diseases. A phase II clinical trial is currently underway for patients with primary sclerosing 
cholangitis (NCT02239211), and further trials in NAFLD are anticipated.   
 
Emricasan is an irreversible caspase inhibitor, which has been investigated in pathways of 
inflammation and apoptosis in liver disease. It was demonstrated to reduce the histological NAS and 
fibrosis scores in murine models of NAFLD (101) and liver enzymes and markers of apoptosis in a 
phase II, placebo control trial in patients with NAFLD and elevated transaminases (102).  A phase IIb 
study in subjects with biopsy-proven NASH and fibrosis is evaluating the efficacy of 72 weeks of 
10mg or 100mg/day of emricasan, the primary endpoint being improvement in fibrosis, and 
secondary endpoint being resolution of NASH (NCT02686762). Emricasan has also shown efficacy in 
reducing the hepatic venous pressure gradient in cirrhotics with portal hypertension(103)  and a 
phase II trial is assessing efficacy of 3 doses of emricasan on portal hypertension in individuals with 
NASH cirrhosis and a hepatic venous pressure gradient ≥12mmHg (NCT02960204). 
 
  
e) Inhibition of de novo lipogenesis (“Lipid altering”) 
Aramchol is an arachidic and cholic acid conjugate that was shown to inhibit stearoyl CoA desaturase 
(SCD) in vitro and de novo lipogenesis in animal models on high fat diet (104, 105). A randomized, 
double-blind, placebo-controlled trial of 60 patients with biopsy-confirmed NAFLD evaluating 100mg 
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and 300mg Aramchol daily for 3 months showed a 12.57% ± 22.14% reduction in liver fat content in 
the 300mg dose group, compared with an insignificant reduction in the 100mg group and an 
increase in those on placebo. However, there were no other significant improvements in metabolic 
parameters and changes in ALT were minimal (106).  Higher doses of aramchol, 400mg and 600mg, 
are currently being tested on individuals with NASH in a 52 week phase IIb study investigating their 
effect on hepatic triglycerides using nuclear magnetic resonance spectroscopy, and NAS score as a 
secondary endpoint (NCT02279524). 
 
Malonyl-CoA is a key regulator of fatty acid metabolism, controlling the balance between de novo 
lipogenesis and fatty acid oxidation (107), and Acetyl Co–A carboxylase (ACC) is an enzyme that 
regulates the conversion of malonyl-CoA to Acetyl Co–A.  Inhibition of ACC in a murine model of 
NAFLD increased fatty acid oxidation, reduced lipogenesis and hepatic fat content, and improved 
insulin sensitivity (107). A phase I trial using an allosteric inhibitor in obese adults demonstrated a 
reduction in de novo lipogenesis (108) and the same compound (GS-9676) is being assessed at two 
dosages for 12 weeks in patients with clinical, radiological or histological NAFLD (NCT02856555). The 
compound is also being compared with 3 others in another study, as mentioned previously. 
 
The thyroid hormone receptor beta (THR-β) is the predominant liver thyroxine (T4) receptor, 
through which increased cholesterol metabolism and excretion through bile is mediated (109).  The 
highly selective (THR-β) agonist MGL-3196 has been developed to target dyslipidaemia but has also 
been shown to reduce liver steatosis in animal models (110); this is now being tested in phase II 
trials in patients with biopsy proven NASH and ≥10% liver steatosis using change from baseline 
hepatic fat fraction assessed by MRI-PDFF as a primary outcome (NCT02912260). 
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f) Targeting the gut microbiome 
IMM-124e is an IgG-rich extract of bovine colostrum from cows immunised against 
lipopolysaccharide (LPS), and is believed to reduce exposure of the liver to gut-derived bacterial 
products and LPS (111). In phase I studies and pre-clinical data, IMM-124 was found to improve liver 
enzymes, insulin resistance (OGTT and HgbA1c), and dyslipidaemia (LDL)(111, 112). A phase II 
RDBPCT is currently evaluating the effects of 24 weeks of IMM-124e in patients with biopsy-proven 
NASH (NCT02316717). 
 
g) Anti-fibrotic agents 
Lysyl oxidase like-2 (LOXL2) is one of a family of enzymes involved in modifying the extracellular 
matrix, promoting cross-linking of cellular collagen, and enhancing fibrosis (113). Serum LOXL2 levels 
have been shown to correlate with fibrosis in NAFLD (114), and an antibody has been developed and 
studied in a phase IIb clinical trial in patients with NAFLD-related fibrosis; the results are yet to be 
published (NCT01672866). The anti-fibrotic potential of the antibody simtuzumab is also being 
investigated in combination with drugs that target the metabolic or inflammatory component of 
NASH (see combination therapies, NCT02466516), and more phase II trials are anticipated.  In 
addition, a LOXL2 enzyme inhibitor has also been developed, and shows promise in pre-clinical 
models of fibrosis (115) 
 
GR-MD-02 is a carbohydrate-based galectin inhibitor that has been shown to reduce hyaluronic acid 
(a marker of fibrosis) in animal models of NASH with fibrosis (116). Phase I clinical studies confirmed 
safety, tolerability, and pharmacokinetics for single and multiple doses of GR-MD-02, and a 
reduction in the non-invasive FibroTest®(116). Phase II studies in patients with advanced fibrosis 
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(NCT02421094) and portal hypertension (NCT02462967) assessed changes in transient elastography 
by MR and Fibroscan, but have not yet been reported. 
 
Combination therapy 
Combination therapy, targeting both inflammation and fibrosis, may be the most effective strategy 
to improve both cardiovascular and liver outcomes, but few of those carried out so far have shown 
improvement in fibrosis. A prospective, double-blind, randomized, placebo-controlled trial in 45 
patients with biopsy proven NASH investigated vitamin E plus vitamin C vs placebo for 6 months, 
showed a significant improvement in fibrosis but no improvement in necro-inflammation or ALT 
(117). Another combination study involving vitamin E with UDCA for two years showed improved 
serum aminotransferases in the combination group compared to UDCA alone, but no changes in 
fibrosis (118).  NASH but not fibrosis improved following 48 weeks of rosiglitazone with no additional 
benefit of metformin or losartan in another combination study (119). In a 12-month prospective 
study in patients with type 2 diabetes, both pioglitazone and the combination of pioglitazone and 
exenatide (synthetic exendin-4) led to significant reductions in liver fat and ALT, and the 
combination therapy was superior (−60 %) compared to pioglitazone alone (−40 %)(120), but no 
combination studies have been carried out in NASH. Targeting fibrosis more directly, Gilead have 
completed a phase II study in selonsertib (a potent ASK1 inhibitor) and simtuzumab, a LOXL2 
antibody, which showed some histological improvement in fibrosis but not NAS score with high dose 
selonsertib, but little suggestion that the addition of simtuzumab was effective (99) (NCT02466516).  
 
Treatment for NASH – what will the model of care be?  
This is an exciting time for pharmacotherapy in NAFLD. Improved understanding of the 
pathophysiology of NASH has facilitated development of new agents, and evidence is emerging that 
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some already established treatments may have additional benefit.  In trials, primary endpoint have 
focused on improvement in liver-related outcomes, namely NASH resolution and improvement in 
fibrosis; these goals have been difficult to achieve, likely due to poor efficacy of treatments tested 
within limited time frames.  Whilst the rationale of treatment for NAFLD is to prevent progression to 
end-stage liver disease, cardiovascular end-points will be critical in enabling licensing of new drugs.  
As NAFLD is an asymptomatic condition with a long natural history, it is difficult to predict how 
patients will perceive the benefits of therapies with few tangible short-term outcomes.  It is likely 
that drugs will need to be well tolerated and relatively side effect-free if patients are to adhere to 
medical therapy. Other challenges relate to the duration of treatment in NAFLD and the role of non-
invasive markers in determining dose and duration of treatment.  
Combination therapy is likely to be the utilised in the future, but with results of phase III studies 
pending, it is difficult to predict which combinations therapies are likely to be most effective.  It 
seems likely that drugs will target different aspects of pathogenesis ie. an anti-fibrotic in 
combination with one that targets de novo lipogenesis, or an anti-inflammatory agent paired with 
one that improves lipid metabolism. There is also the potential for drug therapy to be tailored 
according to patient needs, ie. using drugs that improve glucose metabolism in those with diabetes, 
using therapies that promote weight loss in the obese, or anti-inflammatories or anti-fibrotics in 
those for which these are the predominant histological features. 
Notwithstanding the exciting developments of new pharmacological agents, it is important not to 
lose sight of the importance of modification to not only treat but also to prevent the onset of 
metabolic syndrome and NAFLD. 
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Class Drug Latest phase of development 
in NAFLD 
Preclinical data  Clinical data 
Incretin based 
therapy 
Liraglutide  
(GLP-1 analogue) 
Proof of concept phase IIb trial 
completed 
(approved for use in type 2 
diabetes) 
Improved steatosis,  ALT, and insulin 
sensitivity; hypertension  and cardiac 
hypertrophy also reduced (27) 
Histology: NASH resolution*(28, 32)  
Non-histological: weight loss, improved diabetic 
control 
 Exenatide  
(Synthetic exendin-4) 
Proof of concept phase IIb trial 
completed in patients with 
NASH and diabetes 
(approved for use in type 2 
diabetes) 
Improved steatosis (26, 121) Results from phase IIb trial not published 
Non histological: Improved insulin resistance and 
weight loss (diabetics) (29, 30) 
 Sitagliptin  
(DDP-4 inhibitor) 
Phase IIa trial in NAFLD 
completed 
Approved for use in type 2 
diabetes 
 
Improved steatosis and insulin sensitivity 
(122) 
Histology: improved hepatocyte ballooning and 
reduction in NAS scores in diabetic subjects with 
NASH (35). (Non-histological studies have shown 
mixed results for steatosis (36,38) and no 
improvement in serum markers (37,38)) 
SGLT-2 inhibitor Canagliflozin  
Ipragliflozin  
Luseogliflozin  
Ipragliflozin: Rodent studies 
completed. 
Luseogliflozin: Rodent studies 
completed 
(all approved for use in type 2 
diabetes) 
Ipragliflozin: improved steatosis, apoptosis 
and fibrosis (43-45) 
Luseogliflozin: improved steatosis and 
fibrosis (42) 
Non-histological: weight loss (39) and improved 
ALT/FLI demonstrated in trials for T2DM 
(Canagliflozin, Ipragliflozin) (47, 48, 50) 
PPAR agonists Pioglitazone  
(PPARγ agonist) 
Phase IIb trial completed 
Approved for use in type 2 
diabetes 
Improved inflammation and fibrosis (123) Histology: improved hepatic steatosis, 
inflammation, ballooning and fibrosis (57, 59) 
Non-histological: reduction in death, myocardial 
infarction and stroke in patients with T2DM 
Elafibranor  
(Dual PPARα/δ  
agonist) 
Phase IIb trial in NASH 
completed. Global phase III trial 
recruiting 
 
Improved steatosis, inflammation and 
fibrosis (67) 
Histology: NASH resolution in those with NAS≥4
§
 
(69, 70) 
Saroglitazar  
(Dual PPARα/γ 
agonist) 
Phase IIa trial in NASH and 
diabetes completed. 
Approved for treatment of 
dyslipidaemia in diabetics 
Reduced steatosis, NASH and fibrosis (64) Non-histological: improved ALT , HBA1c and serum 
triglycerides, improved steatosis on USS (65, 66) 
MSDC -0602 
(PPARγ sparing TZD) 
 
Phase IIb Reduced transaminases, histological NASH, 
and stellate cell activation (73) 
Non-histological: Improved fasting glucose and 
HBA1c in patients with diabetes (72) 
FXR-bile acid axis Obeticholic acid 
(Synthetic bile acid) 
Phase IIb trial in NAFLD 
completed in US, Global phase 
III trial recruiting 
Approved for use in PBC in the 
US 
Improved steatosis (124) Histology:  improved NAS scores and fibrosis (82) 
 GS-9674 
(Selective Farnesoid X 
receptor agonist) 
Phase IIa recruiting  Reduce serum transaminases, hepatic 
steatosis and fibrosis in NASH (86) 
- 
 INT-767  
(Dual FXR/TGFR 
agonist) 
Phase I trial anticipated Improved histological NASH in mice (125) - 
 Volixibat  
ASBT inhibitor 
Phase IIa trial in NASH 
recruiting 
Improved glycaemic control in rats (78); 
improved glucose tolerance, reduced 
hepatic triglyceride and total cholesterol 
concentrations, and improved NAFLD 
activity scores in mice (84) 
- 
Sevelamer 
(Bile acid 
sequestrant) 
Animal studies only Reduced steatosis and lobular inflammation 
in mice (79) 
- 
Hormone 
signalling 
BMS-986036  
(Fibroblast growth 
factor 21 analogue) 
Phase IIa trial evaluating effect 
on hepatic fat content 
measured  by MRS in NASH 
registered but not yet 
recruiting 
Improved insulin sensitivity, reduced 
hepatic fat content, and de novo 
lipogenesis in rats  (91) 
- 
 NGM-282  
(Recombinant FGF-19 
variant) 
Phase IIa trial in NASH 
recruiting 
Reduction of hepatic fat, ALT, and improved 
NAS scores (93) 
- 
De novo 
lipogenesis/lipid  
Aramchol  
(arachidic and cholic 
acid conjugate) 
Phase IIa complete. Phase IIb 
trial recruiting 
Reduced de novo lipogenesis (104, 105) Non-histological: reduction in liver fat content by 
MRS at higher dose (106) 
 NDI-010796  
(Acetyl Co–A 
carboxylase inhibitor) 
Phase I trial completed. Phase II 
recruiting 
Increased fatty acid oxidation, reduced 
lipogenesis and hepatic fat content, and 
improved insulin sensitivity in rats (107) 
 
Non-histological: reduced de novo lipogenesis in 
obese adults (108) 
 MGL-3196 (thyroid 
hormone receptor 
beta (THR-β) agonist) 
Phase 1 complete. Phase IIa 
trial recruiting 
Reduced hepatic steatosis as well as 
reduced plasma FFA and triglycerides (110) 
Reductions in LDL cholesterol of up to 30%, and 
trend to reduce triglycerides (109) 
Antioxidant Vitamin E Phase IIb trials completed Reduced steatohepatitis (126) and fibrosis 
(127) 
Histology: reduced steatosis and improved NAS 
scores** 
Non-histological: reduced ALT (59, 75)  
 Cysteamine  
(Aminothiol) 
Proof of concept phase IIb trial 
in children with NAFLD 
completed. 
- Results of proof of concept phase IIb trial not 
published 
Non-histological: reduced AST, ALT and CK-18 
fragment levels (children) (128) 
Targeting 
apoptosis  
Emricasan 
(Caspase inhibitor) 
Phase IIb in NASH and NASH 
cirrhosis recruiting 
Improved NAS score and fibrosis (101) Non-histological: reduced ALT and markers of 
apoptosis (102) 
 Selonsertib  
(ASK-1 inhibitor) 
Phase IIb trial in NASH and 
fibrosis and cirrhosis recruiting 
Reduced hepatic fibrosis, steatosis, and 
insulin resistance in mice (98) 
Histology: improved fibrosis demonstrated in 
phase IIb trial using selonsertib in combination 
with simtuzumab (with no additional benefit of 
simtuzumab) (99) 
 Anti-
inflammatory 
Cenicriviroc 
(C-C chemokine 
receptor types 2/5 
antagonist) 
Phase IIb trial completed. Phase 
III trial opening soon. 
- Histology: Did not meet primary end-point of 2 
point reduction in NAS, but reduced fibrosis 
(secondary end-point) (96) 
Page 31 of 34 Alimentary Pharmacology & Therapeutic
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
32 
 
 
Table 1. Drugs with proven benefit in NAFLD.  
*Defined as the resolution of steatohepatitis (disappearance of hepatocyte ballooning) without worsening of fibrosis by the Kleiner 
fibrosis classification. 
§
Post-hoc analysis demonstrated NAS resolution in those with NAS≥4 resolution. **Defined as an improvement by 1 
or more points in the hepatocellular ballooning score and no increase in fibrosis.   
Trial phases are defined as follows: phase I, safety study; phase IIa – non-histology randomised control trial (RCT); proof of concept phase 
IIb – small histology RCT; phase IIb – large histology RCT.  
 
 BTT1023 
(Anti-VAP antibody) 
 
Phase IIa trial in NAFLD open 
 
Animal data: reduced inflammatory cell 
recruitment and fibrosis (mice) (100) 
- 
Gut microbiome IMM-124e  
(IgG-rich extract of 
bovine colostrum) 
Phase IIa trial in NASH ongoing Improved ALT  and glucose tolerance (111) - 
Anti-fibrotic Simtuzumab 
(LOXL2 antibody) 
Phase IIb trial terminated Reduced collagen cross linking in fibrosis 
models only (129) 
Results of phase IIb trial in NASH and fibrosis not 
published 
Histology: no benefit from the addition of 
simtuzimab to selomsertib in phase IIb 
combination trial (99). 
 GR-MD-02  
(Galectin inhibitor) 
Phase IIa trial completed, 
further proof of concept phase 
IIb in NASH related cirrhosis 
and portal hypertension 
ongoing 
Reduced hyaluronic acid in mice (116) Results of phase IIa trial not published 
Dual therapies Vitamin E + Vitamin C  Proof of concept phase IIb trial 
completed 
- Histology: improved fibrosis (117) 
 Vitamin E + UDCA  Proof of concept phase IIb trial 
completed 
- Histology: no improvement in fibrosis 
Serum markers: improved liver enzymes (118) 
 Selonsertib + 
Simtuzumab  
Proof of concept phase IIb trial 
completed 
- Histology: improved fibrosis (99) 
 Selonsertib + GS-
9674 
Phase IIa recruiting - - 
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Drug Lipid profile Weight Insulin resistance Cardiovascular outcomes 
Pioglitazone No effect Results in weight gain (59) Improves (59) Reduced incidence of MI and 
stroke demonstrated in patients 
with T2MD (58) 
Obeticholic acid Increase in LDL and reduced 
HDL seen in the phase IIb FLINT 
trial (76) 
Weight loss observed in FLINT 
trial (76) 
Improved insulin sensitivity in 
clamp studies during phase IIa 
trial, but higher fasting serum 
insulin and greater hepatic 
insulin resistance by HOMA 
demonstrated in FLINT(76,77) 
No known effect 
Elafibranor Reduced plasma free fatty acid, 
fasting plasma triglycerides, 
and LDL cholesterol levels  (68) 
No effect Improved peripheral and 
hepatic insulin sensitivity in 
obese men (68) 
No known effect 
GLP-1 inhibition No known effect Weight loss (32) Improved peripheral, hepatic 
and adipose insulin resistance 
in subjects with NASH (31) 
Reduced cardiovascular mortality 
(liraglutide) and non-fatal MI and 
stroke (semaglutide) in patients 
with T2DM (34) 
Saroglitazar Improved serum triglycerides in 
patients with NAFLD and 
diabetes (66) 
No effect (65) Improved HBA1c in patients 
with NAFLD and diabetes (66) 
No known effect 
Table 2. Non-liver related benefits for potential NAFLD therapies. MI, myocardial infarct; T2DM, type 2 diabetes mellitus; 
LDL, low-density lipoprotein; HDL, high-density lipoprotein; HOMA, homoeostasis model of assessment. 
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Table 3. Histological benefits demonstrated during clinical trials for potential therapies in NAFLD 
Drug Steatosis Reduction in 
NAS 
NASH 
resolution 
Fibrosis 
Pioglitazone (57)                                                                                                                             
Vitamin E (59,72) 
Obeticholic acid(76) 
Elafibranor (69) 
Liraglutide (32) 
Cenicriviroc (96) 
Vitamin E + Vitamin C(120) 
*NASH resolution with no stipulation of any worsening of fibrosis. 
†
Improved fibrosis demonstrated at meta-
analysis.**Fibrosis measured as secondary end-point in clinical trials. ‡Observed in post-hoc analysis in those with 
NAS≥4. §Reduced progression of fibrosis in those on liraglutide. 
**† 
** 
** 
* 
*‡ 
§ 
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